New in this update: • Biomarkers & Companion Diagnostics — a new Europe-centered tab indexing the actionable biomarkers behind targeted therapy. For each biomarker (EGFR, ALK, BRAF, HER2, PD-L1, BRCA, MSI-H and more) see the validated test method (per the SmPC, under the EU IVD Regulation) and the EU-authorised medicines the result unlocks — then compare them side by side, down to the full label. • Search by molecular target — type a target such as EGFR, PD-1, PARP or CD20 to instantly pull up the matching drug class(es) for side-by-side comparison. As always: an information aid for professionals, not medical advice — always verify against the official EMA SmPC.

Compare a whole drug class side by side — now from the Europe tab too. Type a disease (for example multiple sclerosis, renal cell carcinoma, psoriasis, or myasthenia gravis) and DrugRadar lines up its therapies with their EU and US approval dates and companies. • Read the full EU SmPC and US prescribing information for every drug in a class, in one comparison. • Much larger disease library spanning oncology, neurology, immunology and more. • Smarter, more accurate disease search. • Stability fixes and refinements.

Compare a whole drug class at once. Search a disease - like CML - and compare all its treatments side by side (for example, the six CML tyrosine kinase inhibitors), each with its FDA and EMA approval dates, drug class, and indication. Plus the latest FDA and EMA approvals, including newly added cell & gene therapies.

• Fixed: some recently authorised EU medicines were missing from the Europe list (e.g. seladelpar/Lyvdelzi for PBC, zuranolone/Zurzuvae) • New: "Back to drug" button when jumping from a medicine to its Phase 3 trials • Fixed: view now scrolls to the top when switching tabs • Smoother scrolling when opening and closing a medicine's detail sheet • The information-only disclaimer is now re-confirmed every 30 days • Updated in-app feature tour, including how often the data refreshes

Corrected wording in the Europe tab: medicines in the "Expected" list are now described as awaiting the European Commission decision, without implying the outcome of the CHMP opinion. The decision date shown remains an estimate.

NEW IN 1.2 • Home-screen widget — see the next expected EU decisions for the conditions you follow, at a glance. • Add to Calendar — export estimated EU decision dates as calendar events, with a reminder three days ahead. • Saved searches — bookmark any search and re-run it with one tap, separately on each tab. • Find drugs from your home screen — every EU medicine is now in iOS system search, jumping straight to its detail page. • New quick tour — "What you can do here" walks you through every feature (? button in the header). • Fixes and refinements throughout. Estimated dates remain estimates — always verify against official sources. For information only; not medical advice.